OBiO Technology (Shanghai) Corp., Ltd.

Insights

Insights

Insights

Press Releases

OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product

OBiO Technology (Shanghai) Corp., Ltd. (Stock code: SH688238), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene Therapeutics (Refreshgene).

OBiO Announces Strategic Partnership with Tofflon to Advance Cell and Gene Therapy Development

OBiO Technology (Shanghai) Corp., Ltd. (Stock code: SH688238) today announced that it entered into a strategic cooperation agreement with today announced that it entered into a strategic cooperation agreement with Shanghai Tofflon Science and Technology Co.Ltd.(Stock code:SZ300171).

FDA Acceptance of Drug Master File Marks New Milestone Achieved for OBiO TECH of GMP Plasmid Products

OBiO Technology (Shanghai) Corp., Ltd (Stock code: SH688238) is a biotechnology company focusing on the cell and gene therapy field. Recently announced that the U.S. Food and Drug Administration (FDA) has successfully obtained the GMP plasmid DNA Drug Master File (DMF) filing.

ALL PRESS RELEASES

Events

10th-12th Oct. ,2023

Cell&Gene meeting on the Mesa

Carlsbad, CA, United States

18th-21st Sep. ,2023

BioProcess International Conference & Exhibition

16th-20th May ,2023

ASGCT 26th Annual Meeting

Los Angeles, CA

15th-16th Apr. ,2022

SAPA-GP 2022 Annual Conference (Hybrid)

King of Prussia, PA

16th-19th May ,2022

ASGCT 25th Annual Meeting

Washington, D.C.

15th-16th Jul. ,2022

China Oncolytic Virus Conference 2022 (Hybrid)

Shanghai, China

Knowledge Center

Laboratory Sciences

AAV Packaging Services

Lentivirus Packaging Services

AAV Lung M3 and X

AAVneO + AAVMeta Platform

Off-the-Shelf AAV Products

CDMO Solutions

CGT CDMO Solutions at OBiO

Cell Therapy CDMO Solutions

Adeno Associated Virus CDMO Solutions

IPSC CDMO Services

Phase-Appropriate Plasmid CDMO Solutions

Lentiviral Vector CDMO Solutions

Oncolytic Virus CDMO Solutions

CONTACT US

First Name*

Last Name*

Company*

Email*

Phone Number*

I'm interested in…

Questions or Comments

Code*

I AGREE*

By submitting this form I agree that OBiO may process my data in the manner described in OBiO’s Privacy Policy

We won’t share your information.

OBiO Technology (Shanghai) Corp., Ltd.

About Us
Laboratory Services
Insights
Innovations
Investor Relations

CDMO Solutions: Process Development; cGMP Manufacturing; Quality & Regulatory; Cold Chain Logistics
Privacy Policy

© 2023 OBiO Technology (Shanghai) Corp., Ltd. All Rights Reserved